UKINETS2016 Poster Presentations (1) (35 abstracts)
Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies
Irvin M Modlin 1 , Andrea Frilling 2 , Ronald R Salem 3 , Daniele Alaimo 4 , Panagiotis Drymousis 2 , Harpreet S Wasan 2 , Stephen Callahan 4 , Omar Faiz 5 , Lei Weng 2 , Nancy Teixeira 4 , Lisa Bodei 4 , Ignat Drozdov 4 & Mark Kidd 4
1Emeritus Prof, Yale University School of Medicine, New Haven, USA; 2Department of Surgery and Cancer, Imperial College London, London, UK; 3Department of Surgery, Yale University School of Medicine, New Haven, USA; 4Wren Laboratories, Branford, USA; 5Department of Colorectal Surgery, St Mark’s Hospital, London, UK.
Background: Surgery is the only curative treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), but the prediction of residual disease/recurrence is limited in the absence of optimal biomarkers. We examined whether a blood-based multianalyte neuroendocrine gene transcript assay (NETest) would define tumor cytoreduction and therapeutic efficacy.
Methods: The NETest is a polymerase chain reaction–based analysis of 51 genes. Disease activity is scaled 0–100%; minimal <14%, low 14–47%, and high >47%. A total of 35 GEP-NETs in 2 groups were evaluated. I: after surgery (R0, n=15; residual, n=12); II: nonsurgery (n=8: embolization with gel-foam alone [bland: n=3]), transarterial chemoembolization (n=2), and radiofrequency embolization (n=3). Measurement (quantitative real-time-polymerase chain reaction) and chromogranin A (CgA; enzyme-linked immunosorbent assay) were undertaken preoperatively and 1 month after treatment.
Results: NETest score was increased in 35 (100%) preoperatively; 14 (40%) had increased CgA (χ2=30, P<2×10−8). Resection reduced NETest from 80±5% to 29%±5, (P<.0001). CgA decrease was insignificant (14.3±1.6 U/L to 12.2±1.7 U/L). NETest decreases correlated with diminished tumor volume (R2=0.29, P=0.03). Cytoreduction significantly reduced NETest from 82±3% to 41%±6, P<.0001). CgA was not decreased (21.4±5.5 U/L to 18.4±10.1 U/L). Four (36%) of 11 R0s with increased NETest at 1 month developed positive imaging (sensitivity 100%, specificity 20%). One hundred percent (ablated group) were transcript- and image-positive.
Conclusion: Blood NET transcripts delineate surgical resection/cytoreduction and facilitate identification of residual disease. (Work published).
Keywords: Blood NET transcripts, NETest, gastroenteropancreatic neuroendocrine tumors
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more